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Voices#AStemCellScientistBecauseStem Cell Awareness Day is October 14, 2015. We are marking the occasion in print and social media by
sharing insights from the first authors of the papers in this issue on what inspires and motivates them in their
work as stem cell scientists.Stem Cell HeterogeneityAllison Bond Simon Haas Christina Galonska‘‘The potential resilience that our
stem cells provide is powerful but
remains to be harnessed.’’
Historically, adult neural stem cells
(NSCs) were viewed as a homogeneous
population with an indefinite capacity to
self-renew. When I entered the adult
NSC field, it had become clear that
NSCs are actually heterogeneous and
may have different capacities for self-
renewal, quiescence, and fate choice.
The concept of NSC heterogeneity
suggests that subpopulations of NSCs
contribute different functions to the
NSC population as a whole and must
coordinate to maintain the NSC popula-
tion. An imbalance in these populations
likely compromises NSC maintenance
in damaged or aging NSC populations.
My work is focused on understanding
howheterogeneity is established in adult
NSCs. I have become especially inter-
ested in niche mechanisms from the
surrounding microenvironment because
recent work in our lab found that quies-
cent adult NSCs, the presumed true
NSCs, rely heavily on extrinsic niche sig-
nals to guide their behavior, while acti-
vated NSCs and progenitors transition
to intrinsic transcriptional and transla-
tional programs. I hope that by under-
standing how different niche factors re-
gulate specific subpopulations of NSCs,
we will gain insight into ways we can
modulate NSCs to rejuvenate damaged
oragingNSCpopulationswheremainte-
nance has been compromised.
Johns Hopkins UniversityKeep Your Eyes Wide Open‘‘Unexpected findings and exciting
discoveries are hidden every-
where.’’
I still remember the time back in high
school when I fell in love with science,
with all these new and fancy discov-
eries being made every day. Starting
in the lab and running your own pro-
jects, you quickly realize how slowly
science moves forward compared to
what you thought during those days in
the classroom, and how difficult it can
be to come up with the right project.
Sometimes you have a clear question
to answer, but sometimes keeping
your eyes wide open mixed with a
good portion of luck might be enough
to find an exciting project.
Three years ago, the manuscript that
we now have published in Cell Stem
Cell wasn’t a predefined project, but
rather came from a puzzling finding in
a proteome screen. A large group of
proteins typically expressed in a cell
population very distinct to hemato-
poetic stem cells (HSCs) were highly
upregulated in mouse HSCs upon
exposing the mice to inflammation.
Initially we had strong doubts about
whether it would be smart to follow
such an interesting but difficult-to-
explain finding. Three years later, we
know it was the right way to go!
German Cancer Research Center (DKFZ)Cell Stem Cell 1A Dive into the Ground State‘‘Seeing how stem cells transform
their molecular identity within 1
day is truly impressive.’’
Something that always amazes me
about research is how a multiyear proj-
ect can sometimes be based on a sin-
gle, seemingly random observation.
Needless to say, this was the case for
our current study, too. Back in my early
days as a graduate student, I tested
different culture conditions—one of
them being 2i—on one of our fluores-
cent reporter cell lines for the pluripo-
tency gene Utf1. Just 1 day later I
realized that the Utf1 reporter, which
was highly expressed in serum,
became barely detectable in 2i. Draw-
ing from this single observation and
purely based on curiosity, we started
diving deeper into the matter of ground
state pluripotency to try to figure out
more about the early regulators of
the transition. I still remember that we
were not really expecting to detect
any global changes, but when we
finished analyzing our first data points,
we realized that not only Utf1—which
turned out to be the most divergently
expressed pluripotency marker in 2i—
but the complete pluriptotency network
aroundOct4, Sox2, andNanog became
rapidly reconfigured in this short transi-
tion time. Witnessing how stem cells
transform their molecular identity within
1 day remains very impressive to me
and truly underlines the immense plas-
ticity of the pluripotent state.
Harvard Stem Cell Institute7, October 1, 2015 ª2015 Elsevier Inc. 381
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VoicesFinding IGFBP3’s FunctionFrancesca D’Addio Laura Hamilton Lena Ho‘‘Finding IGFBP3 led me from dia-
betes to regenerative medicine in
unexpected ways.’’
I first ran into the stem cell universe 10
years ago, during my nephrology clin-
ical training, when I was involved in a
project studying renal stem cells in kid-
ney regeneration. What really fasci-
nated me was that our bodies have an
internal repair system with local stem
cell pools in some adult tissues that
guide the replenishment of cells lost in
injury or disease and are capable of
preserving organ homeostasis. These
amazing cells pointed to a new kind
of regenerative medicine for organ
replacement that relied on using stem
cell-based strategies as an alternative
to organ transplantation. But I soon
realized that stem cells are not only an
extraordinary resource for their self-
renewal properties, they may exert
other important effects, for example
by modulating immune responses. I
was fortunate to participate in a multi-
center study demonstrating that a
stem cell-based therapy restores insu-
lin independence in individuals with
new-onset type 1 diabetes by halting
the autoimmune attack toward pancre-
atic islets. As my interest in stem cell
research expanded, I started to work
on intestinal disorders in diabetic pa-
tients and the role of stem cells in their
pathogenesis. This led me on an
exciting journey into the world of intes-
tinal stem cells, what regulates their
fate, and how to preserve their function.
The discovery of the role of IGFBP3 in
controlling intestinal stem cells is now
a new tremendous challenge for me,
and my own way to contribute to stem
cell research in the future.
Boston Children’s Hospital, Harvard University382 Cell Stem Cell 17, October 1, 2015 ª201Every Piece Counts‘‘#Everylittlepiecebringsusonestep-
closer #Alzheimer’sdisease’’
CRCHUM, Universite´ de Montre´alI was that kid who asked ‘‘why?’’ at the
end of every sentence, and frankly, not
much has changed since then. I am
continuously inspired to understand
the causes behind behaviors, occur-
rences, and patterns. As a researcher,
I am fascinated by how your brain
makes you who you are, and by the
devastating consequences of some-
thing going wrong in the brain. My
keen interest in finding solutions to
brain pathologies led me to wonder
about the potential we can unleash
from stem cells. Unfortunately, our un-
derstanding of the human brain and pa-
thologies associated with it is still quite
restricted. However, the deep-seated
need to fill in these blanks is great moti-
vation. There is a real need for innova-
tion and I am excited to hopefully be a
part of it. I believe that a multidisci-
plinary approach to answering the
brain’s most important questions is
the most efficient way to move the field
forward. Looking at the same problem
through the eyes of a chemist or an
anatomist, for example, focuses on
starkly different aspects of the scientific
question at hand and exponentially
opens the possibilities for answering
it. Approaching a major problem and
knowing that I will only in the best of
cases shed light on a little part of the
puzzle still totally inspires me. The dis-
coveries we make as stem cell re-
searchers can impact multiple fields in
ways we can rarely predict, as those
other fields can and have impacted
us. At the end of the day, we are
all working for a common goal, to
contribute a new piece.5 Elsevier Inc.Grand Plans for a Small Peptide‘‘When your PubMed search yields
0 results, rejoice; you’re on to
something truly novel.’’
Until 2 years ago, ELA (Hs. 105196) was
still annotated as a long non-coding
RNA with no known function and no
associated literature. 5 years ago, we
went out on a limb, hypothesizing that
Hs. 105196 contained a small ORF en-
coding a secreted peptide: ‘‘ELA.’’ We
made all reagents, assays, and models
from scratch. It took us 1 year to be
convinced that the peptide existed,
and another 3 years of empirical for-
ward genetics to understand its multi-
faceted roles. The breakthrough came
when we identified APLNR as ELA’s re-
ceptor. However, biology is neither sim-
ple nor straightforward. As it turns out,
ELA has multiple functions mediated
through different receptors, some still
unknown. We eventually found that
ELA is among one of a handful of
secreted factors required for ESCs
(and by inference, human embryos) to
thrive and survive. Along the way,
many naysayers cautioned me to quit.
Why would someone be interested in
a gene with no (known) function?
Today, new indications for ELA (also
known as APELA) are published every
month. We are proud to have discov-
ered it and inspired to continue finding
new peptides in the human genome.
When venturing into the unknown, there
is never a boring day in the lab—only
frustrating and exhilarating ones, at a
ratio of about 29:1. But the feeling
when you’ve uncovered another piece
of Nature’s wondrous design? Sheer
delight. One word of caution: don’t let
skeptics, including and especially your-
self, keep you from making major dis-
coveries!
Institute of Medical Biology, A*STAR
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VoicesEncounter with MEIS1Masayuki Iwasaki Jong Kyoung Kim Aleksandra A. Kolodziejczyk‘‘Understanding the root of leuke-
mias led me on a journey to find
their stem cells.’’
My early studies were stimulated by the
MEIS1 gene, which has the remarkable
property of dramatically enhancing the
oncogenic features of HOX-associated
acute myeloid leukemia (AML) contain-
ing Mixed Lineage Leukemia (MLL)
gene rearrangements. Specifically, I
became interested in howMEIS1 short-
ened the latency of AML. Then, we
demonstrated that MEIS1 served a ma-
jor role in establishing leukemia stem
cell (LSC) potential, and it regulated
LSC frequencies in MLL leukemia.
This finding sparked my interest in
LSCs. LSCs are the ultimate therapeu-
tic target to eradicate AML from the
point of view that LSCs are resistant
to conventional chemotherapy and
facilitate clinical relapse. However,
both HSCs and LSCs share many
characteristics, including self-renewal,
quiescence, and immunophenotype.
This led me to investigate the unique
molecular and biological features of
LSCs. Fortunately, I identified the
LSC-enriched fraction for AML induced
by co-expression of MLL target genes
HOXA9 and MEIS1. Since the LSC fre-
quency is quite high (approximately
10%), I realized that the fractionated
cells would be essential for my investi-
gations and started this project. Thus,
by initially focusing on the unique
role of MEIS1 in leukemia pathogen-
esis, I identified lectin CD93, whose
surface expression correlated with
Meis1 levels, as an LSC-specific sur-
face molecule in MLL-rearranged
AML. The next challenge is to develop
LSC-targeted therapies for clinical
application in the future.
Stanford UniversitySingle-Cell Transcriptomics‘‘The power of single-cell transcrip-
tomics for dissecting stem cell het-
erogeneity inspires me.’’
Recent technological developments for
single-cell transcriptomics have pro-
vided deep insights into the functional
diversity of cells within a tissue in
diverse fields of biology, including
stem cell biology. These emerging ge-
nomics technologies open up several
new avenues of research: they allow
us to dissect regulatory networks that
underlie cell-type-specific responses
within heterogeneous subpopulations,
to delineate cell-to-cell heterogeneity
within a population of cells, and to iden-
tify rare cell types of scientific and clin-
ical interest. By developing computa-
tional methods to analyze single-cell
RNA-seq data, we identified novel
genes of the pluripotency network,
dissected global cell-to-cell variability
in gene expression among different cul-
ture conditions, and found a rare sub-
population resembling the two-cell
state in a population of mouse embry-
onic stem cells. I am excited by the po-
wer of single-cell transcriptomics to
elucidate the heterogeneity of embry-
onic and adult stem cells. In particular,
I am interested in understanding the
roles of chromatin structure and retro-
transposons in cellular heterogeneity
of stem cells. As a computational biolo-
gist, I find that one key challenge is
to develop computational tools for
analyzing big datasets containing thou-
sands of single cells. Ultimately, I would
like to use these tools to understand the
roles of genetic, epigenetic, environ-
mental, and stochastic variation in the
relationship between genotype and
phenotype at the single-cell level.
EMBL-EBICell Stem Cell 1Cellular Heterogeneity‘‘Every cell is special and unique!’’
Wellcome Trust Sanger InstituteSingle-cell transcriptomics is revolu-
tionizing research in the areas of
early development and differentiation
because it is unbiased and more
comprehensive than previous ap-
proaches. This type of data goes
beyond simply analyzing transcript
abundances because it provides the
additional dimension of variation in
these abundances between individual
cells. This has allowed us to identify
subpopulations in mouse ESC cultures,
predict transcription factor regulatory
networks, and even infer relative cell-
cycle speeds.
In our work, we investigated steady-
state cultures of mouse ESCs and
quantified gene expression heteroge-
neity to investigate the sources of cell-
to-cell variation. We found new genes
involved in exit from pluripotency and
provided further characterization of a
rare subpopulation of 2C-like cells.
Personally, I am particularly interested
in understanding in a quantitative and
mechanistic sense how cells traverse
from one state to another. We observed
this phenomenon within our population
of serum-cultured cells, where a subset
of cells exit pluripotency and move
down a differentiation pathway. We
were able to identify the source and
composition of this heterogeneity, but
other aspects of this process remain
understudied. I find it remarkable and
motivating that with a single ‘‘snap-
shot’’ experiment, we were able to un-
ravel and describe dynamic processes:
differentiation and the cell cycle.7, October 1, 2015 ª2015 Elsevier Inc. 383
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VoicesTurn Dreams into RealityStefano La Rosa Masatoshi Ohgushi Michael J. Ziller‘‘Studying stem cells and mor-
phology led me to therapeutic dis-
covery, turning a dream to reality.’’
The relationships between symptoms
and morphological tissue alterations
represent the bridge linking basic sci-
ence to clinical diseases. The dream
of a curious surgical pathologist, as I
am, is to identify the correlation be-
tween morphology and clinical mani-
festations. The history of the present
study embodies such a situation. This
investigation started more than 15
years ago when we began to collect in-
testinal specimens from patients with
type 1 diabetes who were suffering
from gastrointestinal disturbances.
Although at that time we were focused
on conventional histology, thinking
that morphological alterations should
be responsible for the clinical picture,
we rapidly understood that this repre-
sented only one face of the problem
and that something else, not visible
with light microscopy, was involved.
Considering that stem cell function rep-
resents the key point in the mainte-
nance of mucosal integrity, we thought
that colonic stem cells (CoSCs), not
identifiable in conventional histological
slides, may be altered in the course of
the disease. This was the idea leading
us to study, for the first time, CoSCs.
The collaboration with other col-
leagues, many of them dear friends,
with different scientific expertise al-
lowed us to discover that CoSCs are
the target of IGF-I and that altered
IGF-I and IGFBP3 circulating levels
are directly responsible for CoSC ab-
normalities. This is the history of a
dream turned into reality.
Ospedale di Circolo384 Cell Stem Cell 17, October 1, 2015 ª201Tales of ESCs’ Long Lives‘‘Non-transformed cells can’t live
ex vivo indefinitely, but ESCs can.
I want to know why!’’
In my Ph.D. training, I worked on cell
death using a variety of tumor-derived
and primary cultured cells. These expe-
riences brought me to the perspective
that ‘‘cellular immortality’’ is a kind
of anomalous phenotype. Indeed, it
seems quite obvious that cells would
need a panel of genetic mutations or
gene manipulations to circumvent the
limitations imposed by the body. It
really must be hard work for cells to sur-
vive ex vivo.
Having moved to ESC biology, there-
fore, I was wondering, how was it that
they could live and grow in culture for
such a long period? Reflecting their or-
igins, ESCs are in general regarded as
non-transformed cells, but they seem
to share critical features with trans-
formed cells. It seemed strikingly
curious that this property of ESCs looks
reversible. Could such truly plastic
immortality exist? This vague question
motivated me to investigate how ESCs
survive in vitro, and fortunately I found
the Rho-dependent sustained activity
of YAP/TAZ as one mechanism under-
lying this atypical characteristic.
Much luck smiled on me before reach-
ing this finding. The best part for me
was working with Dr. Yoshiki Sasai.
He guided me into the ESC field, and
although I had gone away from his
lab’s main theme, he gave me research
liberty as well as much time for discus-
sion. His extensive interests and
tremendous enthusiasm for science al-
ways inspired me. I’m proud of being
his student, and his teachings will stay
alive in my heart.
RIKEN, CDB5 Elsevier Inc.The 2 i’s‘‘Stem cells offer a glimpse into
how a single genome produces a
variety of cell fates.’’
Tome, one of themost fascinating phe-
nomena in biology is the fact that a sin-
gle genome is utilized to create such a
tremendous variety of transient and
stable cellular states. The serum-to-2i
switch is a remarkable model system
for studying the basic biology of plurip-
otency as well as the mechanics of cell
state transitions. Within a short time
frame of switching culture conditions,
a new cellular state emerges that is
characterized by loss of H3K27me3 at
bivalent genes and the loss of DNA
methylation, although key pluripotency
factors are present in both states. This
rapid, chemically defined transition
provides a great opportunity to study
several dimension of cell state dy-
namics. By peering into cells undergo-
ing a switch from serum to 2i, we were
able to catch a glimpse of this great
architectural complexity. Our study
contributes toward a better under-
standing of the role and interplay of
distinct epigenetic mechanisms in es-
tablishing the 2i gene regulatory
network structure. However, I am fasci-
nated by the remaining questions these
studies leave unanswered, such as the
precise molecular meaning of differen-
tial transcription factor binding and the
mechanisms that lead to the redistribu-
tion of the pluripotency transcription
factors. Ultimately, I would like to define
the context-specific function of each in-
dividual change in transcription factor
occupancy or epigenetic mark with
respect to establishing, maintaining,
and defining the potential of a cellular
state.
Harvard University
